Company

WuXi AppTec Q3 Revenue Jumps 38% as Backlog Hits RMB 76.74 Billion – Full-Year Guidance Raised
Finanical ReportsHKG: 2359

WuXi AppTec Q3 Revenue Jumps 38% as Backlog Hits RMB 76.74 Billion – Full-Year Guidance Raised

WuXi AppTec Co., Ltd. (SHA: 603259; HKG: 2359) released its 2026 third-quarter report, posting Q3 operating revenue of RMB 16.640 billion, up 38.01% year on year (YoY), and net profit…

HutchMed's SANOVO Phase III Hits Primary Endpoint – ORPATHYS Plus TAGRISSO Extends Median PFS to 24.9 Months in MET-Overexpressing EGFR-Mutant NSCLC

HutchMed’s SANOVO Phase III Hits Primary Endpoint – ORPATHYS Plus TAGRISSO Extends Median PFS to 24.9 Months in MET-Overexpressing EGFR-Mutant NSCLC

Regeneron Extends BARDA Agreement With $270 Million Inmazeb Supply Deal for U.S. Ebola Preparedness Through 2031

Regeneron Extends BARDA Agreement With $270 Million Inmazeb Supply Deal for U.S. Ebola Preparedness Through 2031

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Changchun GeneScience Secures China Approval for Long‑Acting FSH‑CTP Injection
GeneScience PharmaceuticalProduct approvals

Changchun GeneScience Secures China Approval for Long‑Acting FSH‑CTP Injection

Ipsen Launches BYLVAY in China for Rare Liver Disease
EPA: IPNIpsen S.A.

Ipsen Launches BYLVAY in China for Rare Liver Disease

TJ Biopharma Secures Series C2 Funding to Accelerate Autoimmune and Oncology Pipeline
BiotechFinance

TJ Biopharma Secures Series C2 Funding to Accelerate Autoimmune and Oncology Pipeline

Full‑Life Technologies Raises $77 M in Series C and Debt Funding
BiotechFinance

Full‑Life Technologies Raises $77 M in Series C and Debt Funding

Show More